Gerrit Dispersyn - RXi Pharmaceuticals Chief Development Officer
Executive
Dr. Gerrit Dispersyn, Med. Sc. is Chief Development Officer of the Company. Dr. Dispersyn is an accomplished leader in clinical, product and business development. Dr. Dispersyn most recently served as the Vice President, Global Head of Clinical Affairs at Integra LifeSciences Corporationrationration. In this role, Gerrit was responsible for Integras global strategy and execution of Clinical Development, Clinical Operations and Medical Affairs projects and a member of Integras Senior Management Leadership team, and several of the companys core teams for MA projects since 2017.
Tenure | 7 years |
Phone | 508-767-3861 |
Web | http://www.rxipharma.com |
RXi Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (96.79) % which means that it has lost $96.79 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (294.79) %, meaning that it created substantial loss on money invested by shareholders. RXi Pharmaceuticals' management efficiency ratios could be used to measure how well RXi Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
Showing other executives | EXECUTIVE Age | ||
Selina Zhang | HUTCHMED DRC | N/A | |
Melik Ulusu | Cytek Biosciences | N/A | |
Nathan Minnich | Treace Medical Concepts | N/A | |
Theresa Mota | SunLink Health Systems | N/A | |
Catherine Lundy | Xtant Medical Holdings | N/A | |
William McCombe | Cytek Biosciences | 66 | |
Aaron Berutti | Treace Medical Concepts | 45 | |
Valerie JD | Cytek Biosciences | 48 | |
Patrik Jeanmonod | Cytek Biosciences | 57 | |
Scot Elder | Treace Medical Concepts | 49 | |
Jill Gilpin | Xtant Medical Holdings | N/A | |
Philippe Busque | Cytek Biosciences | N/A | |
Kin MBA | HUTCHMED DRC | 47 | |
Paul Goode | GlucoTrack | 56 | |
Julie Dewey | Treace Medical Concepts | 63 | |
James Mulligan | SunLink Health Systems | 102 | |
Qingmei Wang | HUTCHMED DRC | 61 | |
Hong Chen | HUTCHMED DRC | 54 | |
Mark Schallenberger | Xtant Medical Holdings | 38 | |
David Ng | HUTCHMED DRC | N/A | |
Allen Poirson | Cytek Biosciences | 64 |
Management Performance
Return On Equity | -294.79 | |||
Return On Asset | -96.79 |
RXi Pharmaceuticals Leadership Team
Elected by the shareholders, the RXi Pharmaceuticals' board of directors comprises two types of representatives: RXi Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of RXi. The board's role is to monitor RXi Pharmaceuticals' management team and ensure that shareholders' interests are well served. RXi Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, RXi Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
Geert Cauwenbergh, President CEO, Director | ||
Robert Bitterman, Director | ||
Pamela Pavco, Chief Devel. Officer | ||
Keith Brownlie, Director | ||
Jonathan Freeman, Independent Director | ||
Gerrit Dispersyn, Chief Development Officer | ||
Curtis Lockshin, Director | ||
Paul Dorman, Independent Director | ||
Alexey Eliseev, Chief Business Officer | ||
Tamara McGrillen, IR Contact Officer |
RXi Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is RXi Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | -294.79 | |||
Return On Asset | -96.79 | |||
Current Valuation | (1.77 M) | |||
Shares Outstanding | 18.16 M | |||
Shares Owned By Insiders | 3.78 % | |||
Shares Owned By Institutions | 10.08 % | |||
Number Of Shares Shorted | 814.04 K | |||
Price To Earning | (0.54) X | |||
Price To Book | 0.84 X | |||
Price To Sales | 39.20 X |
Currently Active Assets on Macroaxis
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Other Consideration for investing in RXi Stock
If you are still planning to invest in RXi Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the RXi Pharmaceuticals' history and understand the potential risks before investing.
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA |